Tarsus Pharmaceuticals Inc expected to post a loss of 94 cents a share - Earnings Preview

* Tarsus Pharmaceuticals Inc is expected to show a rise in quarterly revenue when it reports results on November 13 for the period ending September 30 2024

* The Irvine California-based company is expected to report a 2,221.6% increase in revenue to $43.438 million from $1.87 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Tarsus Pharmaceuticals Inc is for a loss of 94 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Tarsus Pharmaceuticals Inc is 61.50​, above​ its last closing price of $49.08. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jan. 1 0001 -1.21 -0.92 -0.88 Beat 4.8

Mar. 31 0001 -1.21 -1.20 -1.01 Beat 16.2

Dec. 31 2023 -1.39 -1.36 -1.31 Beat 3.9​

Sep. 30 2023 -1.29 -1.37 -1.28 Beat 6.3

​​Jun. -1.06 -1.08 -1.17 Missed -8.5

30 2023

Mar. 31 2023 -0.92 -0.94 -0.88 Beat 6.9​

Jan. 1 0001 -0.69 -0.49 Beat 29

Sep. 30 2022 -0.88 -0.97 -0.84 Beat 13.7

This summary was machine generated November 12 at 03:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)